CorTec Brain Interchange Gains Second FDA Breakthrough Designation
Freiburg, Germany, August 31, 2026 Kazia Therapeutics has announced plans to expand its ongoing paxalisib clinical trial into hormone...
Fulvestrant
Advertisement
Kazia Expands Paxalisib Trial Into HR+ Breast Cancer
Sydney, Australia, September 1, 2026 Kazia Therapeutics has announced plans to expand its ongoing paxalisib clinical trial into hormone...
Celcuity’s Gedatolisib Doubles Progression-Free Survival in Phase 3 Breast Cancer Trial
MINNEAPOLIS, Minnesota, USA , June 2, 2026 Celcuity has announced groundbreaking results from the Phase 3 VIKTORIA-1 clinical trial,...
Avenzo Reports Promising Phase 1 Data for AVZO-021 in HR+ Breast Cancer
SAN DIEGO, Calif., June 1, 2026 Avenzo Therapeutics announced updated clinical results from the Phase 1 portion of its...
Totus Medicines Reports Strong Phase 1b Clinical Results for TOS-358 in HR+/HER2- Breast Cancer
EMERYVILLE, Calif., May 6, 2026 Totus Medicines announced encouraging interim Phase 1b clinical data for its investigational therapy TOS-358...
Advertisement
